A gene expression signature analysis of the baseline tumor samples of patients receiving glofitamab treatment demonstrated significantly lower PD-1-high T-cell signatures in complete responders versus patients with the progression of the disease [49]. The gene discussed is PDCD1; the disease is neoplasm.